ACADIA to Host Conference Call and Webcast on Tuesday, November 7,
2017, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Oct. 31, 2017--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will report its financial results for the third
quarter ended September 30, 2017 on Tuesday, November 7, 2017, after the
U.S. financial markets close. ACADIA's management will host a conference
call and webcast on Tuesday, November 7, 2017, at 5:00 p.m. Eastern Time
to discuss ACADIA’s financial results and operations.
The conference call may be accessed by dialing 844-821-1109 for
participants in the United States or Canada and 830-865-2550 for
international callers (reference passcode 8898709). A telephone replay
of the conference call may be accessed through November 21, 2017 by
dialing 855-859-2056 for callers in the United States or Canada and
404-537-3406 for international callers (reference passcode 8898709). The
conference call also will be webcast live on ACADIA’s website, www.acadia-pharm.com
under the investors section and will be archived there until November
21, 2017.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and
commercialization of innovative medicines that address unmet medical
needs in central nervous system disorders. ACADIA maintains a website at www.acadia-pharm.com
to which we regularly post copies of our press releases as well as
additional information and through which interested parties can
subscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to the progress and timing of ACADIA’s
drug discovery and development programs, and the benefits to be derived
from NUPLAZID® (pimavanserin) and ACADIA’s product
candidates. These statements are only predictions based on current
information and expectations and involve a number of risks and
uncertainties. Actual events or results may differ materially from those
projected in any of such statements due to various factors, including
the risks and uncertainties inherent in drug discovery, development,
approval and commercialization, and in collaborations with others, and
the fact that past results of clinical trials may not be indicative of
future trial results. For a discussion of these and other factors,
please refer to ACADIA’s annual report on Form 10-K for the year ended
December 31, 2016 as well as ACADIA’s subsequent filings with the
Securities and Exchange Commission. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the
date hereof. This caution is made under the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise or
update this press release to reflect events or circumstances after the
date hereof, except as required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171031005443/en/
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Investor
Relations
(858) 558-2871
ir@acadia-pharm.com